Inhibition of phosphodiesterase 4 and 7 regulates breast cancer cell proliferation

cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines. cAMP levels w...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Biochimica et biophysica acta. General subjects Ročník 1869; číslo 11; s. 130850
Hlavní autoři:	Mayora Justel, Carla, Valladares, Tamara, Gargiulo, Lucía, González-Pardo, Verónica, De Sousa, Maximiliano, Esandi, María del Carmen, Davio, Carlos, Lüthy, Isabel, Bruzzone, Ariana
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 01.10.2025
Témata:	1-Methyl-3-isobutylxanthine - pharmacology Aminopyridines - pharmacology Benzamides - pharmacology Breast neoplasm Breast Neoplasms - drug therapy Breast Neoplasms - enzymology Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell line Cell Line, Tumor Cell Movement - drug effects Cell Proliferation - drug effects Cell Survival - drug effects Cyclic AMP Cyclic AMP - metabolism Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism Cyclopropanes - pharmacology Female Gene expression Gene Expression Regulation, Neoplastic - drug effects Humans MCF-7 Cells Phosphodiesterase 4 inhibitor Phosphodiesterase 4 Inhibitors - pharmacology Phosphodiesterase Inhibitors - pharmacology Roflumilast Cyclic AMP Cell line Roflumilast Phosphodiesterase 4 inhibitor Gene expression Breast neoplasm
ISSN:	0304-4165, 1872-8006, 1872-8006
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	cAMP regulates key processes in mammary cell biology. Previous studies suggested reduced cAMP production in more malignant cells. This study investigates the role of cAMP in mammary biology using non-tumor (MCF-10A and HBL-100) and tumor (MCF-7 and MDA-MB-231) human breast cell lines. cAMP levels were quantified using a competitive radio-binding assay. Cell proliferation and viability were assessed by cell counting and MTT assay. Gene expression was analyzed by real-time PCR and immunofluorescence. Additional assays included migration, colony formation, annexin V/IP staining, comet assay, and caspase-3 activity. Public datasets were consulted. Phosphodiesterase (PDE) inhibitors were tested: the broad-spectrum PDE inhibitor IBMX (3-Isobutyl-1-methylxanthine), the PDE4-selective inhibitor roflumilast, and the PDE7-selective inhibitor BRL-50481. Non-tumor cells produced more cAMP than tumor cells, with or without IBMX. IBMX decreases cell proliferation and viability in all cell lines. Gene expression data revealed higher ADCY2, 3, 4, 5, 6, and 8 expression in normal tissues. Roflumilast reduced cell viability in all tested cells, while the PDE7-specific inhibitor BRL-50481 only affected MCF-7 cells. All PDE inhibitors exhibited an additive effect with tamoxifen, reducing MCF-7 cell viability. In tumor cells roflumilast decreased cell migration. In MDA-MB-231 cells, although IBMX and roflumilast showed a trend toward further decreasing viability compared to doxorubicin or paclitaxel alone, the differences were not statistically significant. The selective PDE4 inhibitor roflumilast demonstrated potential as a therapeutic agent when combined with specific breast cancer treatments, offering a novel approach in breast cancer therapy. •cAMP levels are higher in non-tumor breast cells compared to breast cancer cells.•ADCY gene expression is lower in tumor tissues compared to normal tissues.•PDE4D expression is elevated in MDA-MB-231 breast cancer cells.•Roflumilast reduces migration and cell viability in breast cancer cell lines.•PDE inhibitors enhance tamoxifen effects in MCF-7 breast cancer cells.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0304-4165 1872-8006 1872-8006
DOI:	10.1016/j.bbagen.2025.130850